Maxim Group Downgrades Aclarion(ACON.US) to Hold Rating
Ascendiant Maintains Aclarion(ACON.US) With Buy Rating, Cuts Target Price to $1.3
Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $1.3
Aclarion Analyst Ratings
Aclarion Price Target Cut to $1.50/Share From $1.60 by Ascendiant Capital
Aclarion Analyst Ratings
Maxim Group Maintains Aclarion(ACON.US) With Buy Rating
Maxim Group Maintains Aclarion(ACON.US) With Buy Rating
Maxim Group Remains a Buy on Aclarion, Inc. (ACON)
Ascendiant Capital Initiates Coverage On Aclarion With Buy Rating, Announces Price Target of $1.6
Aclarion Analyst Ratings
Ascendiant Initiates Aclarion(ACON.US) With Buy Rating, Announces Target Price $1.6
Analysts Are Bullish on Top Healthcare Stocks: Calliditas Therapeutics (CALT), Aclarion, Inc. (ACON)
Aclarion, Inc. (ACON) Receives a Buy From Maxim Group